{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T16:40:27Z","timestamp":1781023227415,"version":"3.54.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T00:00:00Z","timestamp":1663372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T00:00:00Z","timestamp":1663372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s00392-022-02108-w","type":"journal-article","created":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T14:02:26Z","timestamp":1663423346000},"page":"299-311","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Hypercholesterolemia diagnosis, treatment patterns and target achievement in patients with acute coronary syndromes in Germany"],"prefix":"10.1007","volume":"112","author":[{"given":"Anselm K.","family":"Gitt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus G.","family":"Parhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Laufs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried","family":"M\u00e4rz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Dieter","family":"Paar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4970-2110","authenticated-orcid":false,"given":"Peter","family":"Bramlage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaus","family":"Marx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,17]]},"reference":[{"key":"2108_CR1","unstructured":"WHO (2021) Cardiovascular disease fact sheet. Cardiovascular diseases (CVDs). https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cardiovascular-diseases-(cvds). Accessed 14 Sept 2022"},{"issue":"11","key":"2108_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030442","volume":"3","author":"CD Mathers","year":"2006","unstructured":"Mathers CD, Loncar D (2006) Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3(11):e442","journal-title":"PLoS Med"},{"issue":"17","key":"2108_CR3","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1001\/jama.297.17.1892","volume":"297","author":"KA Fox","year":"2007","unstructured":"Fox KA, Steg PG, Eagle KA, Goodman SG, Anderson FA Jr, Granger CB, Flather MD, Budaj A, Quill A, Gore JM et al (2007) Decline in rates of death and heart failure in acute coronary syndromes, 1999\u20132006. JAMA 297(17):1892\u20131900","journal-title":"JAMA"},{"issue":"1","key":"2108_CR4","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA et al (2020) 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41(1):111\u2013188","journal-title":"Eur Heart J"},{"issue":"13","key":"2108_CR5","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","volume":"285","author":"GG Schwartz","year":"2001","unstructured":"Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T (2001) Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285(13):1711\u20131718","journal-title":"JAMA"},{"issue":"9493","key":"2108_CR6","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","volume":"366","author":"C Baigent","year":"2005","unstructured":"Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R et al (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493):1267\u20131278","journal-title":"Lancet"},{"issue":"9374","key":"2108_CR7","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","volume":"361","author":"R Collins","year":"2003","unstructured":"Collins R, Armitage J, Parish S, Sleigh P, Peto R (2003) Heart Protection Study Collaborative G: MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361(9374):2005\u20132016","journal-title":"Lancet"},{"issue":"9435","key":"2108_CR8","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","volume":"364","author":"HM Colhoun","year":"2004","unstructured":"Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364(9435):685\u2013696","journal-title":"Lancet"},{"issue":"9784","key":"2108_CR9","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","volume":"377","author":"C Baigent","year":"2011","unstructured":"Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J et al (2011) The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377(9784):2181\u20132192","journal-title":"Lancet"},{"issue":"10","key":"2108_CR10","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1093\/oxfordjournals.eurheartj.a015136","volume":"18","author":"EUROASPIRE","year":"1997","unstructured":"EUROASPIRE (1997) A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J 18(10):1569\u20131582","journal-title":"Eur Heart J"},{"issue":"6","key":"2108_CR11","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1177\/2047487315569401","volume":"23","author":"K Kotseva","year":"2016","unstructured":"Kotseva K, Wood D, De Bacquer D, De Backer G, Ryden L, Jennings C, Gyberg V, Amouyel P, Bruthans J, Castro Conde A et al (2016) EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol 23(6):636\u2013648","journal-title":"Eur J Prev Cardiol"},{"issue":"4","key":"2108_CR12","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00392-010-0240-9","volume":"100","author":"AK Gitt","year":"2011","unstructured":"Gitt AK, Junger C, Jannowitz C, Karmann B, Senges J, Bestehorn K (2011) Adherence of hospital-based cardiologists to lipid guidelines in patients at high risk for cardiovascular events (2L registry). Clin Res Cardiol 100(4):277\u2013287","journal-title":"Clin Res Cardiol"},{"issue":"4","key":"2108_CR13","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1097\/HJR.0b013e32832a4e25","volume":"16","author":"AK Gitt","year":"2009","unstructured":"Gitt AK, Juenger C, Jannowitz C, Karmann B, Senges J, Bestehorn K (2009) Guideline-oriented ambulatory lipid-lowering therapy of patients at high risk for cardiovascular events by cardiologists in clinical practice: the 2L cardio registry. Eur J Cardiovasc Prev Rehabil 16(4):438\u2013444","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"issue":"2","key":"2108_CR14","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1177\/1741826711400545","volume":"19","author":"AK Gitt","year":"2012","unstructured":"Gitt AK, Drexel H, Feely J, Ferrieres J, Gonzalez-Juanatey JR, Thomsen KK, Leiter LA, Lundman P, da Silva PM, Pedersen T et al (2012) Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada. Eur J Prev Cardiol 19(2):221\u2013230","journal-title":"Eur J Prev Cardiol"},{"issue":"19\u201320","key":"2108_CR15","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s00508-011-0057-1","volume":"123","author":"H Drexel","year":"2011","unstructured":"Drexel H, Chazelle F, Fauer C, Lautsch D, Gitt AK (2011) Persistent dyslipidemia in Austrian patients treated with statins for primary and secondary prevention of atherosclerotic events - Results of the DYSlipidemia International Study (DYSIS). Wien Klin Wochenschr 123(19\u201320):611\u2013617","journal-title":"Wien Klin Wochenschr"},{"issue":"14","key":"2108_CR16","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","volume":"32","author":"Z Reiner","year":"2011","unstructured":"European Association for Cardiovascular P, Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E et al (2011) ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 32(14):1769\u20131818","journal-title":"Eur Heart J"},{"issue":"39","key":"2108_CR17","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","volume":"37","author":"AL Catapano","year":"2016","unstructured":"Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR et al (2016) 2016 ESC\/EAS guidelines for the management of dyslipidaemias. Eur Heart J 37(39):2999\u20133058","journal-title":"Eur Heart J"},{"issue":"15","key":"2108_CR18","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1136\/heartjnl-2013-305196","volume":"100","author":"R Andre","year":"2014","unstructured":"Andre R, Bongard V, Elosua R, Kirchberger I, Farmakis D, Hakkinen U, Fusco D, Torre M, Garel P, Araujo C et al (2014) International differences in acute coronary syndrome patients\u2019 baseline characteristics, clinical management and outcomes in Western Europe: the EURHOBOP study. Heart 100(15):1201\u20131207","journal-title":"Heart"},{"issue":"23\u201324","key":"2108_CR19","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s00508-018-1375-3","volume":"130","author":"AK Gitt","year":"2018","unstructured":"Gitt AK, Rieber J, Hambrecht R, Brachmann J, Graf K, Horack M, Karmann B, Vyas A, Lautsch D, Ambegaonkar B et al (2018) Do acute coronary events affect lipid management and cholesterol goal attainment in Germany? Results from the Dyslipidemia International study II. Wien Klin Wochenschr 130(23\u201324):707\u2013715","journal-title":"Wien Klin Wochenschr"},{"issue":"3","key":"2108_CR20","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1177\/2047487318817082","volume":"26","author":"B Schwaab","year":"2019","unstructured":"Schwaab B, Zeymer U, Jannowitz C, Pittrow D, Gitt A (2019) Improvement of low-density lipoprotein cholesterol target achievement rates through cardiac rehabilitation for patients after ST elevation myocardial infarction or non-ST elevation myocardial infarction in Germany: Results of the PATIENT CARE registry. Eur J Prev Cardiol 26(3):249\u2013258","journal-title":"Eur J Prev Cardiol"},{"issue":"18","key":"2108_CR21","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM et al (2017) Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376(18):1713\u20131722","journal-title":"N Engl J Med"},{"issue":"1","key":"2108_CR22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1080\/14712598.2020.1677604","volume":"20","author":"D Steffens","year":"2020","unstructured":"Steffens D, Bramlage P, Scheeff C, Kasner M, Hassanein A, Friebel J, Rauch-Kr\u00f6hnert U (2020) PCSK9 inhibitors and cardiovascular outcomes. Expert Opin Biol Ther 20(1):35\u201347","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"2108_CR23","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1161\/CIRCULATIONAHA.118.038840","volume":"140","author":"PG Steg","year":"2019","unstructured":"Steg PG, Szarek M, Bhatt DL, Bittner VA, Bregeault MF, Dalby AJ, Diaz R, Edelberg JM, Goodman SG, Hanotin C et al (2019) Effect of alirocumab on mortality after acute coronary syndromes. Circulation 140(2):103\u2013112","journal-title":"Circulation"},{"issue":"18","key":"2108_CR24","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1016\/j.jacc.2020.03.029","volume":"75","author":"DL Bhatt","year":"2020","unstructured":"Bhatt DL, Briggs AH, Reed SD, Annemans L, Szarek M, Bittner VA, Diaz R, Goodman SG, Harrington RA, Higuchi K et al (2020) Cost-effectiveness of alirocumab in patients with acute coronary syndromes: the ODYSSEY OUTCOMES trial. J Am Coll Cardiol 75(18):2297\u20132308","journal-title":"J Am Coll Cardiol"},{"key":"2108_CR25","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.1016\/j.atherosclerosissup.2021.01.009","volume":"42","author":"U Landmesser","year":"2020","unstructured":"Landmesser U, Pirillo A, Farnier M, Jukema JW, Laufs U, Mach F, Masana L, Pedersen TR, Schiele F, Steg G et al (2020) Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: the ACS patient pathway project. Atheroscler Suppl 42:e49\u2013e58","journal-title":"Atheroscler Suppl"},{"issue":"2","key":"2108_CR26","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/HJR.0b013e3283294b1d","volume":"16","author":"K Kotseva","year":"2009","unstructured":"Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Keil U, Group ES (2009) EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 16(2):121\u2013137","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"2108_CR27","doi-asserted-by":"publisher","DOI":"10.1177\/2047487319838218","author":"T Tiffe","year":"2019","unstructured":"Tiffe T, Morbach C, Malsch C, Gelbrich G, Wahl V, Wagner M, Kotseva K, Wood D, Leyh R, Ertl G et al (2019) Physicians' lifestyle advice on primary and secondary cardiovascular disease prevention in Germany: a comparison between the STAAB cohort study and the German subset of EUROASPIRE IV. Eur J Prev Cardiol. https:\/\/doi.org\/10.1177\/2047487319838218","journal-title":"Eur J Prev Cardiol"},{"issue":"24","key":"2108_CR28","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.018897","volume":"9","author":"BE Claessen","year":"2020","unstructured":"Claessen BE, Guedeney P, Gibson CM, Angiolillo DJ, Cao D, Lepor N, Mehran R (2020) Lipid management in patients presenting with acute coronary syndromes: a review. J Am Heart Assoc 9(24):e018897","journal-title":"J Am Heart Assoc"},{"key":"2108_CR29","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.atherosclerosis.2016.01.018","volume":"246","author":"Z Reiner","year":"2016","unstructured":"Reiner Z, De Backer G, Fras Z, Kotseva K, Tokgozoglu L, Wood D, De Bacquer D, Investigators E (2016) Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries\u2013findings from the EUROASPIRE IV survey. Atherosclerosis 246:243\u2013250","journal-title":"Atherosclerosis"},{"issue":"7","key":"2108_CR30","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40266-020-00768-9","volume":"37","author":"I Dykun","year":"2020","unstructured":"Dykun I, Wiefhoff D, Totzeck M, Al-Rashid F, Janosi RA, Hendricks S, Rassaf T, Mahabadi AA (2020) Treatment patterns of lipid-lowering therapy in patients with coronary artery disease aged above and below 75 years: a retrospective cross-sectional study of 1500 patients in a tertiary care referral center in Germany. Drugs Aging 37(7):521\u2013527","journal-title":"Drugs Aging"},{"issue":"6","key":"2108_CR31","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1177\/2048872616679791","volume":"7","author":"F Schiele","year":"2018","unstructured":"Schiele F, Farnier M, Krempf M, Bruckert E, Ferrieres J, French G (2018) A consensus statement on lipid management after acute coronary syndrome. Eur Heart J Acute Cardiovasc Care 7(6):532\u2013543","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2108_CR32","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2147\/VHRM.S197089","volume":"15","author":"S Wassmuth","year":"2019","unstructured":"Wassmuth S, Rohe K, Noack F, Noutsias M, Treede H, Schlitt A (2019) Adherence to lipid-lowering therapy in patients with coronary heart disease from the state of Saxony-Anhalt, Germany. Vasc Health Risk Manag 15:477\u2013483","journal-title":"Vasc Health Risk Manag"},{"issue":"2","key":"2108_CR33","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1093\/ehjcvp\/pvz079","volume":"6","author":"H Drexel","year":"2020","unstructured":"Drexel H, Coats AJS, Spoletini I, Bilato C, Mollace V, Perrone Filardi P, Rosano GMC (2020) An expert opinion paper on statin adherence and implementation of new lipid-lowering medications by the ESC Working Group on Cardiovascular Pharmacotherapy: Barriers to be overcome. Eur Heart J Cardiovasc Pharmacother 6(2):115\u2013121","journal-title":"Eur Heart J Cardiovasc Pharmacother"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-022-02108-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-022-02108-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-022-02108-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T13:07:05Z","timestamp":1675429625000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-022-02108-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,17]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["2108"],"URL":"https:\/\/doi.org\/10.1007\/s00392-022-02108-w","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,17]]},"assertion":[{"value":"10 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AKG, KGP, UL, WM, B and NM have received research support and\/or consulting honoraria from different makers of lipid-lowering drugs including Sanofi. PB received funding for drafting the first version of the manuscript from Sanofi.\u00a0WDP is an employee of and is holding stock in Sanofi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}